LM Advisors’s Oramed Pharmaceuticals ORMP Stock Holding History

LM Advisors’s Portfolio ORMP Stock Details ORMP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-2,500	Closed	-$5.78K	–	568
2023 Q4	$5.78K	Buy	+2,500	New	+$5.34K	﹤0.01%	581

Other funds holding ORMP

Murchinson Toronto, Ontario, Canada $791M AUM 68.08% 1-Year Est. Return

BCM

BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Rathbones Group Liverpool, United Kingdom $25B AUM 18.87% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

LM Advisors's ORMP Position: Q1 2024 in Review

LM Advisors sold out of Oramed Pharmaceuticals (ORMP) in Q1 2024, closing a stake of 2,500 shares — an estimated $5.78K sold.

LM Advisors first reported a position in ORMP in Q4 2023 and held it in 1 quarter. The position peaked at $5.78K in Q4 2023. 51 funds tracked by Wall St. Rank hold ORMP as of Q1 2024.

LM Advisors reported no remaining Oramed Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
LM Advisors sold 2,500 Oramed Pharmaceuticals shares in Q1 2024, an estimated $5.78K.
LM Advisors first reported a position in Oramed Pharmaceuticals in Q4 2023 and held it in 1 quarter.
LM Advisors's Oramed Pharmaceuticals position peaked at $5.78K in Q4 2023.
51 funds tracked by Wall St. Rank held Oramed Pharmaceuticals as of Q1 2024.

Based on LM Advisors's 13F filing for Q1 2024, filed 15 May 2024.